About Type 2 diabetes, Centers for Disease Control and Prevention (2024) Glucagon-like peptide 1 (GLP-1), Molecular Metabolism (2019) GLP-1 receptor agonists and the risk of thyroid cancer, Diabetes Care (2023) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes, JAMA (2022) Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34), Lancet (1998) Standards of medical care in diabetes2022, Clinical Diabetes (2022) Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy, New England Journal of Medicine (2019) Tirzepatide versus semaglutide once weekly in patients with Type 2 diabetes, New England Journal of Medicine (2021) Living healthy with diabetes, American Heart Association (2024) The effect of berberine supplementation on obesity parameters, inflammation, and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials, Clinical Nutrition ESPEN (2020) Efficacy and safety of berberine alone for several metabolic disorders: A systematic review and meta-analysis of randomized clinical trials, Frontiers in Pharmacology (2021) Switching between glucagon-like peptide-1 receptor agonists: Rational and practical guidance, Clinical Diabetes (2020) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

Bostock ECS, Kirkby KC, Taylor B V, Hawrelak JA
Latham states that she was prescribed Ozempic in August 2022, and received weekly injections until at least July 2023
This delivery method allows medication to go directly into the body, rather than through the digestive system
(PubMed) Jirong Y, Huiyun P, Zhongzhe Y, et al